Animal models to assess the toxicity, immunogenicity and effectiveness of candidate influenza vaccines

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 9, 2011, Pages 1117-1127

  Eichelberger, Maryna C ^a   Green, Martin D ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Attenuated; Inactivated; Influenza; Live; Pandemic; Seasonal vaccines

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; SUBUNIT VACCINE;

CAT; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; FERRET; HAPLORHINI; HUMAN; IMMUNOGENICITY; INFLUENZA; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; REVIEW; SWINE;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION;

ANIMALIA;

EID: 80051906313     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.602065     Document Type: Review

References (100)

1. WHO. Influenza fact sheet 211. Available from: Http://www.who.int/ mediacentre/ factsheets/fs211/en/index.html [Last accessed 1 December 2010]
2. WHO. Recommendations for influenza vaccines. Available from: Http://www. who.int/csr/disease/influenza/ vaccinerecommendations/en/index.html [Last accessed 1 December 2010]
3. Tosh PK, Jacobson RM, Poland GA. Influenza vaccines: From surveillance through production to protection. Mayo Clin Proc 2010;85:257-73
4. Bodewes R, Rimmelzwaan GF, Osterhaus AD. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev Vaccines 2010;9:59-72
5. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med 2010;363:2036-44
6. CDC. Avian influenza A virus infections of humans. Available from: Http://www. cdc.gov/flu/avian/gen-info/avian-fluhumans. htm [Last accessed 7 April 2011]
7. Chen GL, Subbarao K. Live attenuated vaccines for pandemic influenza. Curr Top Microbiol Immunol 2009;333:109-32
8. Horimoto T, Kawaoka Y. Designing vaccines for pandemic influenza. Curr Top Microbiol Immunol 2009;333:165-76
9. Sambhara S, Poland GA. H5N1 Avian influenza: Preventive and therapeutic strategies against a pandemic. Annu Rev Med 2010;61:187-98
10. Du L, Zhou Y, Jiang S. Research and development of universal influenza vaccines. Microbiol Infect 2010;12:280-6
11. Roose K, Fiers W, Saelens X. Pandemic preparedness: Toward a universal influenza vaccine. Drug News Perspect 2009;22:80-92
12. DiMenna LJ, Ertl HC. Pandemic influenza vaccines. Curr Top Microbiol Immunol 2009;333:291-321
13. Rimmelzwaan GF, Kreijtz JH, Bodewes R, et al. Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 2009;27:6363-5
14. Fiers W, De Filette M, El Bakkouri K, et al. M2e-based universal influenza A vaccine. Vaccine 2009;27:6280-3
15. Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009;16:265-73
16. Tripp RA, Tompkins SM. Animal models for evaluation of influenza vaccines. Curr Top Microbiol Immunol 2009;333:397-412
17. Suzuki Y, Ito T, Suzuki T, et al. Sialic acid species as a determinant of the host range of influenza A viruses. J Virol 2000;74:11825-31
18. Neumann G, Kawaoka Y. Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis 2006;12:881-6
19. Chen H, Bright RA, Subbarao K, et al. Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice. Virus Res 2007;128:159-63
20. Nakajima E, Morozumi T, Tsukamoto K, et al. A naturally occurring variant of porcine Mx1 associated with increased susceptibility to influenza virus in vitro. Biochem Genet 2007;45:11-24
21. Doherty PC, Brown LE, Kelso A, et al. Immunity to avian influenza A viruses. Rev Sci Tech 2009;28:175-85
22. Peiris JS, Hui KP, Yen HL. Host response to influenza virus: Protection versus immunopathology. Curr Opin Immunol 2010;22:475-81
23. Tamura M, Webster RG, Ennis FA. Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses. J Virol 1994;68:3499-504
24. Aldridge JR, Moseley CE, Boltz DA, et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. PNAS 2009;106:5306-11
25. Babiuk S, Skowronski DM, De Serres G, et al. Aggregate content influences the Th1/Th2 immune response to influenza vaccine: Evidence from a mouse model. J Med Virol 2004;72:138-42
26. Kistner O, Crowe BA, Wodal W, et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One 2010;5:e9349
27. Belser JA, Wadford DA, Pappas C, et al. Pathogenesis of pandemic influenza A (H1N1) and triple-reassortant swine influenza A (H1) viruses in mice. J Virol 2010;84:4194-203
28. Zhou B, Li Y, Belser JA, et al. NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. Vaccine 2010;28:8015-25
29. Kash JC, Tumpey TM, Proll SC, et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006;443:578-81
30. Narasaraju T, Sim MK, Ng HH, et al. Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: Insights into viral virulence, tissue tropism and host pathogenesis. Microbiol Infect 2009;11:2-11
31. Mestas J, Hughes CC. Of mice and not men: Differences between mouse and human immunology. J Immunol 2004;172:2731-8
32. Eichelberger MC. The cotton rat as a model to study influenza pathogenesis and immunity. Viral Immunol 2007;20:243-9
33. Ottolini MG, Blanco JC, Eichelberger MC, et al. The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J Gen Virol 2005;86:2823-30
34. Eichelberger MC, Prince GA, Ottolini MG. Influenza-induced tachypnea is prevented in immune cotton rats, but cannot be treated with an anti-inflammatory steroid or a neuraminidase inhibitor. Virology 2004;322:300-7
35. Stertz S, Dittmann J, Blanco JC, et al. The antiviral potential of interferon-induced cotton rat Mx proteins against orthomyxovirus (influenza), rhabdovirus, and bunyavirus. J Interferon Cytokine Res 2007;27:847-55
36. Phair JP, Kauffman CA, Jennings R, et al. Influenza virus infection of the guinea pig: Immune response and resistance. Med Microbiol Immunol 1979;165:241-54
37. Sun Y, Bi Y, Pu J, et al. Guinea pig model for evaluating the potential public health risk of swine and avian influenza viruses. PLoS ONE 2010;5:e15537
38. Lowen AC, Mubareka S, Tumpey TM, et al. The guinea pig as a transmission model for human influenza viruses. PNAS 2006;103:9988-92
39. Lowen AC, Steel J, Mubareka S, et al. Blocking interhost transmission of influenza virus by vaccination in the guinea pig model. J Virol 2009;83:2803-18
40. Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenza patients. Lancet 1933;ii:66-8
41. Van Der Laan JW, Herberts C, Lambkin-Williams R, et al. Animal models in influenza vaccine testing. Expert Rev Vaccines 2008;7:783-93
42. Govorkova EA, Rehg JE, Krauss S, et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 2005;79:2191-8
43. Karron RA, Talaat K, Luke C, et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009;27:4953-60
44. Maassab HF, DeBorde DC. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 1985;3:355-69
45. CDC. The 2009 H1N1 pandemic: Summary highlights, April 2009-April 2010. Available from: Http://www.cdc. gov/h1n1flu/cdcresponse.htm [Last accessed 4 December 2010]
46. Shope RE, Francis T. The Susceptibility of Swine to the Virus of Human Influenza. J Exp Med 1936;64:791-801
47. Khatri M, Dwivedi V, Krakowka S, et al. Swine influenza H1N1 virus induces acute inflammatory immune responses in pig lungs: A potential animal model for human H1N1 influenza virus. J Virol 2010;84:11210-18
48. Van Reeth K, Van Gucht S, Pensaert M. Correlations between lung proinflammatory cytokine levels, virus replication, and disease after swine influenza virus challenge of vaccination-immune pigs. Viral Immunol 2002;15:583-94
49. Van Reeth K, Labarque G, De Clercq S, et al. Efficacy of vaccination of pigs with different H1N1 swine influenza viruses using a recent challenge strain and different parameters of protection. Vaccine 2001;19:4479-86
50. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009;460:1021-5
51. Haverson K, Saalmuller A, Alvarez B, et al. Overview of the Third International workshop on Swine Leukocyte differentiation antigens. Vet Immunol Immunopathol 2001;80:5-23
52. Maines TR, Jayaraman A, Belser JA, et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009;325:484-7
53. Kuiken T, Rimmelzwaan G, Van Riel D, et al. Avian H5N1 influenza in cats. Science 2004;306:241
54. Rimmelzwaan GF, Van Riel D, Baars M, et al. Influenza A virus (H5N1) infection in cats causes systemic disease with potential novel routes of virus spread within and between hosts. Am J Pathol 2006;168:176-83
55. Van Den Brand JM, Stittelaar KJ, Van Amerongen G, et al. Experimental pandemic (H1N1) 2009 virus infection of cats. Emerg Infect Dis 2010;16:1745-7
56. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010;16:915-20
57. Kunzi V, Klap JM, Seiberling MK, et al. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. Vaccine 2009;27:3561-7
58. Vardaxis NJ, Brans TA, Boon ME, et al. Confocal laser scanning microscopy of porcine skin: Implications for human wound healing studies. J Anat 1997;190:601-11
59. Hammond SA, Tsonis C, Sellins K, et al. Transcutaneous immunization of domestic animals: Opportunities and challenges. Adv Drug Deliv Rev 2000;43:45-55
60. Baskin CR, Garcia-Sastre A, Tumpey TM, et al. Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed macaques (Macaca nemestrina). J Virol 2004;78:10420-32
61. Rimmelzwaan GF, Baars M, Van Beek R, et al. Induction of protective immunity against influenza virus in a macaque model: Comparison of conventional and ISCOM vaccines. J Gen Virol 1997;78:757-65
62. Villinger F, Miller R, Mori K, et al. IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccine 2004;22:3510-21
63. Rimmelzwaan GF, Kuiken T, Van Amerongen G, et al. Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol 2001;75:6687-91
64. Kobasa D, Takada A, Shinya K, et al. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 2004;431:703-7
65. Kreijtz JH, Suezer Y, De Mutsert G, et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis 2009;199:405-13
66. Del Giudice G, Stittelaar KJ, Van Amerongen G, et al. Seasonal influenza vaccine provides priming for A/ H1N1 immunization. Sci Transl Med 2009;1:12
67. Van Den Brand JM, Kreijtz JH, Bodewes R, et al. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J Virol 2011;85:2851-8
68. Lu X, Tumpey TM, Morken T, et al. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 1999;73:5903-11
69. Subbarao K, Chen H, Swayne D, et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003;305:192-200
70. Baras B, Stittelaar KJ, Simon JH, et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008;3:e1401
71. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-51
72. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009;361:2405-13
73. Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: A preliminary report of two randomised controlled phase 2 trials. Lancet 2010;375:41-8
74. Cheong HJ, Song JY, Heo JY, et al. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. Vaccine 2011;29:523-7
75. Van Puijenbroek EP, Broos N, Van Grootheest K. Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands. Drug Saf 2010;33:1097-108
76. Vellozzi C, Broder KR, Haber P, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010;28:7248-55
77. Chen H, Matsuoka Y, Swayne D, et al. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 2003;21:4430-6
78. Chen GL, Lamirande EW, Yang CF, et al. Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets. J Virol 2010;84:7695-702
79. Katz JM, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989;160:191-8
80. Guidance for Industry -Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications, 2010. Available from: Http://www.fda.gov/ downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatory Information/Guidances/Vaccines/ UCM202439.pdf [Last accessed 5 December 2010]
81. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001;19:1732-7
82. Johansson BE. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 1999;17:2073-80
83. Kang SM, Song JM, Quan FS, et al. Influenza vaccines based on virus-like particles. Virus Res 2009;143:140-6
84. Galarza JM, Latham T, Cupo A. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005;18:365-72
85. Pushko P, Tumpey TM, Bu F, et al. Influenza virus-like particles comprised of the HA. NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005;23:5751-9
86. WHO. Annex 1, WHO guidelines on nonclinical evaluation of vaccines. WHO Technical Report Series No. 927, 2005. Available from: Http://www.who.int/ biologicals/publications/trs/areas/vaccines/ nonclinical-evaluation/ANNEX% 201Nonclinical.P31-63.pdf [Last accessed 5 December 2010]
87. Code of Federal Regulations -21CFR 210.11. Available from: Http://www. accessdata.fda.gov/scripts/cdrh/cfdocs/ cfcfr/CFRSearch.cfm? fr=610.11&SearchTerm=general% 20safety%20test [Last accessed 5 December 2010]
88. Mizukami T, Masumi A, Momose H, et al. An improved abnormal toxicity test by using reference vaccine-specific body weight curves and histopathological data for monitoring vaccine quality and safety in Japan. Biologicals 2009;37:8-17
89. Advisory Group on Alternatives to Animal Testing in Immunobiologicals. The target animal safety test -Is it still relevant? Biologicals 2002;30:277-87
90. De Mattia F, Chapsal JM, Descamps J, et al. The consistency approach for quality control of vaccines -A strategy to improve quality control and implement 3Rs. Biologicals 2011;39:59-65
91. Cussler K. A 4R concept for the safety testing of immunobiologicals. Dev Biol Stand 1999;101:121-6
92. Schechtman LM. Implementation of the 3Rs (refinement, reduction, and replacement): Validation and regulatory acceptance considerations for alternative toxicological test methods. ILAR J 2002;43:S85-94
93. Code of Federal Regulations -21CFR 210.13. Available from: Http://www. accessdata.fda.gov/scripts/cdrh/cfdocs/ cfcfr/CFRSearch.cfm? fr=610.13&SearchTerm=pyrogen [Last accessed 5 December 2010]
94. Therapeutic Goods Administration. Overview of vaccine regulation and safety monitoring and investigation into adverse events following 2010 seasonal influenza vaccination in young children. Available from: Http://www.tga.gov.au/ alerts/ medicines/vaccine-overview. htm#attachments [Last accessed 5 December,2010]
95. Therapeutic Goods Administration. TGA seasonal trivalent influenza vaccine laboratory investigation program. Available from: Http://www.tga.gov.au/ alerts/medicines/vaccine-overview.htm [Last accessed 5 December 2010]
96. Cash E, Charreire J, Rott O. B-cell activation by superstimulatory influenza virus hemagglutinin: A pathogenesis for autoimmunity? Immunol Rev 1996;152:67-88
97. Scheifele DW, Duval B, Russell ML, et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: Evidence from a controlled trial involving adults. Clin Infect Dis 2003;36:850-7
98. Skowronski DM, Lu H, Warrington R, et al. Does antigen-specific cytokine response correlate with the experience of oculorespiratory syndrome after influenza vaccine? J Infect Dis 2003;187:495-9
99. Janjua NZ, Skowronski DM, Hottes TS, et al. Seasonal influenza vaccine and increased risk of pandemic A/H1N1- related illness: First detection of the association in British Columbia, Canada. Clin Infect Dis 2010;51:1017-27
100. Monsalvo AC, Batalle JP, Lopez MF, et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 2011;17:195-9